Meridian Bioscience (VIVO) 10-Q 4 Feb 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 31, 2021	Jan. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Registrant Name	MERIDIAN BIOSCIENCE, INC.
Entity Central Index Key	0000794172
Entity File Number	0-14902
Entity Tax Identification Number	31-0888197
Entity Incorporation, State or Country Code	OH
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	3471 River Hills Drive
Entity Address, City or Town	Cincinnati
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45244
City Area Code	513
Local Phone Number	271-3700
Trading Symbol	VIVO
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		43,541,412

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
NET REVENUES	$ 88,341	$ 92,917
COST OF SALES	39,182	31,369
GROSS PROFIT	49,159	61,548
OPERATING EXPENSES
Research and development	6,194	5,651
Selling and marketing	7,741	7,021
General and administrative	14,660	11,938
Selected legal costs	281	1,227
Change in fair value of acquisition consideration	0	1,047
Total operating expenses	28,876	26,884
OPERATING INCOME	20,283	34,664
OTHER INCOME (EXPENSE)
Interest income	1	9
Interest expense	(372)	(534)
RADx grant income	0	800
Other, net	(161)	(691)
Total other expense, net	(532)	(416)
EARNINGS BEFORE INCOME TAXES	19,751	34,248
INCOME TAX PROVISION	4,411	7,469
NET EARNINGS	$ 15,340	$ 26,779
Earnings Per Share Data:
BASIC EARNINGS PER COMMON SHARE	$ 0.35	$ 0.62
DILUTED EARNINGS PER COMMON SHARE	$ 0.35	$ 0.61
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	43,439	43,098
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS	589	681
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	44,028	43,779
ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units	425	258

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
NET EARNINGS	$ 15,340	$ 26,779
Other comprehensive (loss) income:
Foreign currency translation adjustment	(58)	3,301
Unrealized gain on cash flow hedge	550	21
Reclassification of amortization of gain on cash flow hedge	0	(77)
Income taxes related to items of other comprehensive (loss) income	(135)	14
Other comprehensive income, net of tax	357	3,259
COMPREHENSIVE INCOME	$ 15,697	$ 30,038

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 15,340	$ 26,779
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	1,700	1,508
Amortization of intangible assets	2,483	2,221
Stock-based compensation	1,903	1,241
Deferred income taxes	927	(852)
Change in fair value of acquisition consideration	0	1,047
Change in the following:
Accounts receivable	9,424	(1,776)
Inventories	2,093	(5,941)
Prepaid expenses and other current assets	200	2,682
Accounts payable and accrued expenses	1,018	(5,826)
Income taxes payable	1,113	4,032
Other, net	(646)	6
Net cash provided by operating activities	35,555	25,121
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(1,708)	(2,086)
Payment of acquisition consideration holdback	0	(5,000)
Net cash used in investing activities	(1,708)	(7,086)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of deferred financing costs	(404)	0
Payment on revolving credit facility	(10,000)	(10,000)
Proceeds from exercise of stock options	80
Employee taxes paid upon net share settlement of restricted share units	(763)	0
Net cash used in financing activities	(11,087)	(10,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	198	1,644
Net Increase in Cash and Cash Equivalents	22,958	9,679
Cash and Cash Equivalents at Beginning of Period	49,771	53,514
Cash and Cash Equivalents at End of Period	$ 72,729	$ 63,193

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 72,729	$ 49,771
Accounts receivable, less allowances of $1,293 and $1,078, respectively	44,300	53,568
Inventories, net	74,198	76,842
Prepaid expenses and other current assets	12,426	12,626
Total current assets	203,653	192,807
PROPERTY, PLANT AND EQUIPMENT, at Cost
Land	987	989
Buildings and improvements	33,009	32,765
Machinery, equipment and furniture	79,438	78,410
Construction in progress	10,352	9,991
Subtotal	123,786	122,155
Less: accumulated depreciation and amortization	80,500	78,941
Property, plant and equipment, net	43,286	43,214
OTHER ASSETS
Goodwill	114,713	114,668
Other intangible assets, net	81,658	84,151
Right-of-use assets, net	5,431	5,786
Deferred income taxes	8,813	8,731
Other assets	1,086	365
Total other assets	211,701	213,701
TOTAL ASSETS	458,640	449,722
CURRENT LIABILITIES
Accounts payable	16,293	11,701
Accrued employee compensation costs	12,029	16,853
Accrued product recall costs	4,269	5,100
Acquisition consideration	1,000	0
Current operating lease obligations	2,057	1,990
Current government grant obligations	765	638
Other accrued expenses	8,667	7,027
Income taxes payable	4,866	3,848
Total current liabilities	49,946	47,157
NON-CURRENT LIABILITIES
Acquisition consideration	0	1,000
Post-employment benefits	2,169	2,253
Long-term operating lease obligations	3,529	3,932
Long-term debt	50,000	60,000
Government grant obligations	5,068	5,176
Long-term income taxes payable	469	469
Deferred income taxes	2,067	1,055
Other non-current liabilities	173	378
Total non-current liabilities	63,475	74,263
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 43,514,258 and 43,361,898 shares issued and outstanding, respectively
Additional paid-in capital	148,623	147,403
Retained earnings	196,041	180,701
Accumulated other comprehensive income	555	198
Total shareholders' equity	345,219	328,302
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 458,640	$ 449,722

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 1,293	$ 1,078
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	43,514,258	43,361,898
Common Stock, shares, outstanding	43,514,258	43,361,898

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Sep. 30, 2020	$ 247,629		$ 140,195	$ 109,294	$ (1,860)
Beginning balance, Shares at Sep. 30, 2020		43,069
Conversion of restricted share units and exercise of stock options	(41)		(41)
Conversion of restricted share units and exercise of stock options, Shares		55
Stock compensation expense	1,241		1,241
Net earnings	26,779			26,779
Foreign currency translation adjustment	3,301				3,301
Hedging activity, net of tax	(42)				(42)
Ending balance at Dec. 31, 2020	278,867		141,395	136,073	1,399
Ending balance, Shares at Dec. 31, 2020		43,124,000
Beginning balance at Sep. 30, 2021	328,302		147,403	180,701	198
Beginning balance, Shares at Sep. 30, 2021		43,362,000
Conversion of restricted share units and exercise of stock options	(683)		(683)
Conversion of restricted share units and exercise of stock options, Shares		152
Stock compensation expense	1,903		1,903
Net earnings	15,340			15,340
Foreign currency translation adjustment	(58)				(58)
Hedging activity, net of tax	415				415
Ending balance at Dec. 31, 2021	$ 345,219		$ 148,623	$ 196,041	$ 555
Ending balance, Shares at Dec. 31, 2021		43,514,000

Nature of Business

Nature of Business	3 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Meridian Bioscience, Inc. (“Meridian” or “the Company”) was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, various Polymerase Chain Reaction (“PCR”) master mixes, and bioresearch reagents used by other diagnostic manufacturers and researchers. Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of: (i) manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi’in, Israel; (ii) manufacturing operations for blood chemistry products in Billerica, Massachusetts; and (iii) the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood. The Life Science segment consists of: (i) manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany; and (ii) the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents domestically and abroad, including a sales and business development facility, with outsourced distribution capabilities, in Beijing, China to pursue revenue opportunities in Asia. This segment’s products are used by manufacturers and researchers in a variety of applications (e.g., in vitro medical device manufacturing, microRNA detection, next-generation sequencing, plant genotyping, and mutation detection, among others).

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The Condensed Consolidated Financial Statements are unaudited and are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial information, and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the Condensed Consolidated Financial Statements include all normal adjustments and disclosures necessary to present fairly the Company’s consolidated financial position as of December 31, 2021, and the results of its operations, cash flows, and shareholders’ equity for the three months ended December 31, 2021 and 2020. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s fiscal 2021 Annual Report on Form 10-K, It should be noted that the terms revenue and/or revenues are utilized throughout these notes to the Condensed Consolidated Financial Statements to indicate net revenue and/or net revenues. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the year. The preparation of these Condensed Consolidated Financial Statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the period. Included within these estimates are those related to the ongoing impacts of the COVID-19

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2021 Annual Report on Form 10-K, (a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2021, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12 Pronouncements Issued but Not Yet Adopted as of December 31, 2021 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Condensed Consolidated Financial Statements. (b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	4. Revenue Recognition Revenue Disaggregation The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only): Net Revenues by Reportable Segment & Geographic Region Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Americas $ 26,613 $ 23,551 13 % EMEA 6,093 6,020 1 % ROW 498 750 (34 )% Total Diagnostics 33,204 30,321 10 % Life Science- Americas 8,137 18,755 (57 )% EMEA 28,648 32,311 (11 )% ROW 18,352 11,530 59 % Total Life Science 55,137 62,596 (12 )% Consolidated $ 88,341 $ 92,917 (5 )% Net Revenues by Product Platform/Type Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Molecular assays $ 4,752 $ 4,590 4 % Non-molecular 28,452 25,731 11 % Total Diagnostics $ 33,204 $ 30,321 10 % Life Science- Molecular reagents $ 31,488 $ 46,029 (32 )% Immunological reagents 23,649 16,567 43 % Total Life Science $ 55,137 $ 62,596 (12 )% Net Revenues by Disease State (Diagnostics segment only) Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Gastrointestinal assays $ 21,619 $ 15,452 40 % Respiratory illness assays 6,380 4,806 33 % Blood chemistry assays 78 4,394 (98 )% Other 5,127 5,669 (10 )% Total Diagnostics $ 33,204 $ 30,321 10 % Royalty Income Royalty income received from a third party related to sales of H. pylori Non-molecular Reagent Rental Arrangements Revenue allocated to the lease elements of Reagent Rental arrangements totaled approximately $ and $ in the months ended December , and , respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements To limit exposure to volatility in the LIBOR interest rate, the Company has entered into interest rate swap agreements, which effectively convert the variable interest rate on the outstanding revolving credit facility discussed in Note 12 to a fixed rate. The fair values of the interest rate swap agreements were determined by reference to a third-party valuation, which is considered a Level 2 input within the fair value hierarchy of valuation techniques, and totaled a $347 asset and a liability, as of December 31, 2021 and September 30, 2021, respectively. As indicated in Note 6, we acquired the BreathTek business on July 31, 2021. The fair values of inventories acquired were valued using Level 2 inputs, which included data points that were observable, such as established values of comparable assets and historical sales information (market approach). Identifiable intangible assets, specifically the acquired customer relationships, were valued using Level 3 inputs, which are unobservable by nature, and included internal estimates of future cash flows and attrition rates (income approach). Significant increases (decreases) in any of those unobservable inputs, as of the date of the acquisition, in isolation would result in a significantly lower (higher) fair value measurement.

Business Combinations

Business Combinations	3 Months Ended
	Dec. 31, 2021
Business Combinations [Abstract]
Business Combinations	6. Business Combinations On July 31 H. pylori holdback, which is recorded in acquisition consideration on the Condensed Consolidated Balance Sheets, to secure the selling party’s performance of certain post-closing obligations that is payable 15 months following the BreathTek acquisition date. As part of the acquisition, we acquired BreathTek inventories and assumed the customer relationships to supply the BreathTek product in North America. The acquired inventories and customer relationships were valued on July 31, 2021 on a preliminary basis, at . There have been no material purchase price adjustments to the preliminary inventories and customer relationships values through December 31, 2021. The Company’s consolidated results for the three-month period ended December 31, 2021 include The following table provides the unaudited consolidated pro forma results for the periods presented as if the BreathTek business had been acquired as of the beginning of fiscal 2021: Three Months Ended December 31, 2021 2020 Net revenues $ 88,341 $ 97,824 Net earnings 15,340 28,014

Lead Testing Matters

Lead Testing Matters	3 Months Ended
	Dec. 31, 2021
Lead Testing Matters [Abstract]
Lead Testing Matters	7. Lead Testing Matters On September 1, 2021, the Company’s wholly owned subsidiary Magellan announced the expansion of a Class I voluntary recall of its LeadCare test kits for the detection of lead in blood, which it had initiated in May 2021. Customers generally run controls when they receive a new lot of product and reported to us that the control results were outside of specified ranges. As a result of the identified issue, impacted test kit lots could potentially underestimate blood lead levels when processing patient blood samples. Although it was initially believed that the root cause of the issue related to the plastic containers used for the treatment reagent, additional studies have indicated that the root cause relates to the third-party-sourced cardboard trays that hold the containers used for the treatment reagent. The Company continues to work closely with the FDA in its execution of the recall activities, which include notifications to customers and distributors, and providing instructions for the return of impacted test kits. The evaluation of the recall, the related notification process and correction of the identified supplier issue is ongoing. Of the approximate estimated and accrued as of September 30, 2021 to cover the estimated costs of the recall, approximately remains accrued and is reflected in the Condensed Consolidated Balance Sheet as of December 31, 2021. Anticipated recall-related costs, which primarily include product replacement and/or refund costs, mailing/shipping costs, attorneys’ fees, and other miscellaneous costs are estimated based upon the most recent information available. Information utilized in the accrual estimation process includes observable inputs such as customer on-hand As previously disclosed, o n April 17, 2018 , the Company’s wholly owned subsidiary Magellan received a subpoena from the U.S. Department of Justice (“DOJ”) regarding its LeadCare product line. The subpoena outlined documents to be produced, and the Company is cooperating with the DOJ in this matter. The Company maintains rigorous policies and procedures to promote compliance with applicable regulatory agencies and requirements, and is working with the DOJ to promptly respond to the subpoena, including responding to additional information requests that have followed receipt of the subpoena in April 2018. The Company has executed tolling agreements to extend the statute of limitations. In March and April 2021, DOJ issued two subpoenas calling for witnesses to testify before a federal grand jury related to this matter. The March 2021 subpoena was issued to a former employee of Magellan, and the April 2021 subpoena was issued to a current employee of Magellan. In September and October 2021, DOJ issued additional subpoenas to individuals seeking testimony and documents in connection with its ongoing investigation. It is the Company’s understanding that multiple witnesses have testified before the federal grand jury and the DOJ’s activity before the federal grand jury is ongoing. The Company cannot predict when the investigation will be resolved, the outcome of the investigation, or its potential impact on the Company. Approximately $281 and $1,227

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	8. Cash and Cash Equivalents Cash and cash equivalents include the following: December 31, September 30, Institutional money market funds $ 1,020 $ 1,020 Cash on hand, unrestricted 71,709 48,751 Total $ 72,729 $ 49,771 Cash equivalents, institutional money market funds, are classified within Level 1 of the fair value hierarchy. Financial instruments classified as Level 1 are based on quoted market prices in active markets. The Company does not adjust the quoted market price for such financial instruments.

Inventories, Net

Inventories, Net	3 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories, Net	9. Inventories, Net Inventories, net, are comprised of the following: December 31, September 30, Raw materials $ 15,104 $ 14,843 Work-in-process 21,479 25,072 Finished goods - instruments 2,699 2,260 Finished goods - kits and reagents 34,916 34,667 Total $ 74,198 $ 76,842

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	3 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	10. Goodwill and Other Intangible Assets, Net Goodwill is not amortized but is subject to an annual impairment test. Goodwill has been assigned to reporting units within the reportable segments. The Company assesses the carrying value of goodwill annually, or more often if events or changes in circumstances indicate there may be impairment. Impairment testing is performed at a reporting unit level. During the three months ended December 31, 2021, goodwill increased $45, reflecting: (i) a $4 increase from the currency translation adjustment on goodwill in the Diagnostics segment; and (ii) a $41 increase from the currency translation adjustment on goodwill in the Life Science segment. A summary of other intangible assets, net, subject to amortization is as follows: December 31, 2021 September 30, 2021 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,421 $ 23,592 $ 62,416 $ 22,633 Trade names, licenses and patents 18,495 9,806 18,489 9,492 Customer lists, customer relationships and supply agreements 54,954 20,887 54,941 19,649 Non-compete 110 37 110 31 Total $ 135,980 $ 54,322 $ 135,956 $ 51,805 The aggregate amortization expense for these other intangible assets was $2,483 and $2,221 for the three months ended December 31, 2021 and 2020 , respectively.

Leasing Arrangements

Leasing Arrangements	3 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leasing Arrangements	11. Leasing Arrangements The Company is party to several operating leases, the majority of which are related to office, warehouse and manufacturing space. The related operating lease assets and obligations are reflected within right-of-use The lease costs for these operating leases reflected in our Condensed Consolidated Statements of Operations, as well as the right-of-use Three Months Ended December 31, 2021 2020 Lease costs within cost of sales $ 225 $ 158 Lease costs within operating expenses 388 374 Right-of-use , 218 80 In addition, the Company periodically enters into other short-term operating leases, generally with an initial term of twelve months or less. These leases are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is immaterial for the three months ended December 31, 2021 and 2020. The Company often has options to renew lease terms, with the exercise of lease renewal options generally at the Company’s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The discount rate implicit within our leases is generally not determinable and, therefore, the Company uses its incremental borrowing rate as the basis for its discount rate. The weighted average remaining lease term for our operating leases and the weighted average discount rate used to measure our operating leases were as follows: December 31, September 30, Weighted average remaining lease term 3.3 years 3.6 years Average discount rate 3.2 % 3.2 % Maturities of lease liabilities by fiscal year for the Company’s operating leases were as follows as of December 31, 2021: 2022 (represents remainder of fiscal year) $ 1,687 2023 1,690 2024 1,218 2025 908 2026 316 Thereafter 62 Total lease payments 5,881 Less amount of lease payments representing interest (295 ) Total present value of lease payments $ 5,586 Supplemental cash flow information related to the Company’s operating leases is as follows: Three Months Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 627 $ 494

Bank Credit Arrangements

Bank Credit Arrangements	3 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Bank Credit Arrangements	12. Bank Credit Arrangements The Company maintains a revolving credit facility with a commercial bank, which on October 25, 2021, was amended primarily to: (i) increase the borrowing capacity from $150,000 to $200,000; (ii) extend the term from May 24, 2024 to October 25, 2026; and (iii) modify the financial covenants to more closely align with the Company’s size and strategic plans. Other provisions of the credit facility remain unchanged. Outstanding principal amounts bear interest at a fluctuating rate tied to, at the Company’s option, either the federal funds rate or LIBOR, resulting in an effective interest rate of 2.22% and 2.54% on the revolving credit facility during the three months ended December 31, 2021 and 2020, respectively. In light of the interest being determined on a variable rate basis, the fair value of the borrowings under the revolving credit facility at both December 31, 2021 and September 30, 2021, approximates the current carrying value reflected in the Condensed Consolidated Balance Sheets of $50,000 and $60,000, respectively, which is consistent with a level 2 fair value measurement. The revolving credit facility is collateralized by the business assets of the Company’s U.S. subsidiaries and requires compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the revolving credit facility agreement. As of December 31, 2021, the Company was in compliance with all covenants.

Contingent Obligations and Non-

Contingent Obligations and Non-Current Liabilities	3 Months Ended
	Dec. 31, 2021
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Contingent Obligations and Non-Current Liabilities	13. Contingent Obligations and Non-Current In connection with the acquisition of Exalenz Bioscience Ltd. (“Exalenz”) in fiscal 2020, the Company assumed several Israeli government grant obligations. The repayment of the grants, along with interest incurred at varying stated fixed rates based on LIBOR at the time each grant was received, is not dictated by an established repayment schedule. Rather, the grants and related interest are required to be repaid using 3% of the net revenues generated from the sales of BreathID products, with the timing of repayment contingent upon the level and timing of such revenues. In addition, the grants have no collateral or financial covenant provisions generally associated with traditional borrowing instruments. T The grant obligations are reflected in the Condensed Consolidated Balance Sheets as follows: December 31, September 30, Current liabilities $ 765 $ 638 Non-current $ 5,068 $ 5,176 Additionally, the Company has provided certain post-employment benefits to its former Chief Executive Officer, and these obligations total $1,639 and $1,676 at December 31, 2021 and September 30, 2021, respectively. In addition, the Company is required by the governments of certain foreign countries in which we operate to maintain a level of accruals for potential future severance indemnity. These accruals total $707 and $754 at December 31, 2021 and September 30, 202 1

National Institutes of Health C

National Institutes of Health Contracts	3 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
National Institutes of Health Contracts	14. National Institutes of Health Contracts In December 2020, the Company entered into a sub-award SARS-CoV-2 Effective February 1, 2021, the Company entered into a second grant contract under the RADx initiative, the purpose of which is to support the Company’s manufacturing production scale-up COVID-19 COVID-19 As of December 31, 2021: (i) Balance Sheet; and (ii) the Company was in the process of finalizing an amendment to the grant, which among other things, would increase the grant by $ 2,500 8,000

Reportable Segment and Major Cu

Reportable Segment and Major Customers Information	3 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Reportable Segment and Major Customers Information	15. Reportable Segment and Major Customers Information The Company’s reportable segments maintain separate financial information for which results of operations are evaluated on a regular basis by the Company’s chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company records the direct costs of business operations to the reportable segments, including allocations for certain corporate-wide costs such as treasury management, human resources and technology, among others. Corporate provides certain executive management and administrative services to each reportable segment. These services primarily include executive oversight by non-segment-specific Reportable segment and corporate information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended December 31, 2021 Net revenues - Third-party $ 33,204 $ 55,137 $ — $ — $ 88,341 Inter-segment 34 55 — (89 ) — Operating (loss) income (2,612 ) 26,517 (3,637 ) 15 20,283 Goodwill (December 31, 2021) 94,908 19,805 — — 114,713 Other intangible assets, net (December 31, 2021) 81,656 2 — — 81,658 Total assets (December 31, 2021) 352,318 106,339 — (17 ) 458,640 Three Months Ended December 31, 2020 Net revenues - Third-party $ 30,321 $ 62,596 $ — $ — $ 92,917 Inter-segment 69 18 — (87 ) — Operating (loss) income (1,182 ) 39,797 (3,963 ) 12 34,664 Goodwill (September 30, 2021) 94,904 19,764 — — 114,668 Other intangible assets, net (September 30, 2021) 84,149 2 — — 84,151 Total assets (September 30, 2021) 339,208 110,536 — (22 ) 449,722 (1) Includes selected legal costs of $281 and $1,227 in the three months ended December 31, 2021 and 2020, respectively. (2) Eliminations consist of inter-segment transactions. A reconciliation of reportable segment operating (loss) income to consolidated earnings before income taxes for the three months ended December 31, 2021 and 2020, is as follows: Three Months Ended December 31, 2021 2020 Operating (loss) income: Diagnostics segment $ (2,612 ) $ (1,182 ) Life Science segment 26,517 39,797 Eliminations 15 12 Total operating income 23,920 38,627 Corporate expenses (3,637 ) (3,963 ) Interest income 1 9 Interest expense (372 ) (534 ) RADx initiative grant income — 800 Other, net (161 ) (691 ) Consolidated earnings before income taxes $ 19,751 $ 34,248 Transactions between reportable segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation. Net revenues generated by the Company’s three major Diagnostics segment product families – gastrointestinal, respiratory illnesses and blood chemistry – accounted for 32% and 27% of consolidated net revenues during the three months ended December 31, 2021 and 2020, respectively. Three individual Diagnostics and two Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows: Three Months Ended December 31, 2021 2020 Diagnostics Customer A 10 % 12 % Customer B 11 % 10 % Customer C 11 % 11 % Life Science Customer D 14 % 19 % Customer E 23 % 2 % In addition, the two Life Science segment customers, including their affiliates, identified above accounted for greater than 10% of consolidated net revenues as follows: Three Months Ended December 31, 2021 2020 Life Science Customer D 9 % 13 % Customer E 14 % 2 % No During the three months ended December 31, 2021 and 2020, the Life Science segment’s ten largest customers, including their affiliates, accounted for approximately 67% and 55%, respectively, of Life Science segment net revenues, and 42% and 37%, respectively, of consolidated net revenues. No Diagnostics or Life Science segment customer accounted for greater than 10% of consolidated accounts receivable as of December 31, 2021, while one Diagnostics segment customer (Customer B above) and one Life Science segment customer (Customer D above) accounted for approximately 12% and 10%, respectively, of consolidated accounts receivable as of September 30, 2021.

Income Taxes

Income Taxes	3 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The effective rate for income taxes was approximately 22% for each of the three months ended December 31, 2021 and 2020.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Event On January 25, 2022, the Company entered into an amended grant contract under the RADx initiative. The purpose of this grant is to support the Company’s manufacturing production scale-up COVID-19 COVID-19

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Recent Accounting Pronouncements	(a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2021, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12 Pronouncements Issued but Not Yet Adopted as of December 31, 2021 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Condensed Consolidated Financial Statements.
Reclassifications	(b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Dec. 31, 2021
Revenue Recognition [Abstract]
Summary of Disaggregation of Revenue	The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only): Net Revenues by Reportable Segment & Geographic Region Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Americas $ 26,613 $ 23,551 13 % EMEA 6,093 6,020 1 % ROW 498 750 (34 )% Total Diagnostics 33,204 30,321 10 % Life Science- Americas 8,137 18,755 (57 )% EMEA 28,648 32,311 (11 )% ROW 18,352 11,530 59 % Total Life Science 55,137 62,596 (12 )% Consolidated $ 88,341 $ 92,917 (5 )% Net Revenues by Product Platform/Type Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Molecular assays $ 4,752 $ 4,590 4 % Non-molecular 28,452 25,731 11 % Total Diagnostics $ 33,204 $ 30,321 10 % Life Science- Molecular reagents $ 31,488 $ 46,029 (32 )% Immunological reagents 23,649 16,567 43 % Total Life Science $ 55,137 $ 62,596 (12 )% Net Revenues by Disease State (Diagnostics segment only) Three Months Ended December 31, 2021 2020 Inc (Dec) Diagnostics- Gastrointestinal assays $ 21,619 $ 15,452 40 % Respiratory illness assays 6,380 4,806 33 % Blood chemistry assays 78 4,394 (98 )% Other 5,127 5,669 (10 )% Total Diagnostics $ 33,204 $ 30,321 10 %

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Dec. 31, 2021
BreathTek [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	The following table provides the unaudited consolidated pro forma results for the periods presented as if the BreathTek business had been acquired as of the beginning of fiscal 2021: Three Months Ended December 31, 2021 2020 Net revenues $ 88,341 $ 97,824 Net earnings 15,340 28,014

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	3 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	Cash and cash equivalents include the following: December 31, September 30, Institutional money market funds $ 1,020 $ 1,020 Cash on hand, unrestricted 71,709 48,751 Total $ 72,729 $ 49,771

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Components of Inventories	Inventories, net, are comprised of the following: December 31, September 30, Raw materials $ 15,104 $ 14,843 Work-in-process 21,479 25,072 Finished goods - instruments 2,699 2,260 Finished goods - kits and reagents 34,916 34,667 Total $ 74,198 $ 76,842

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	3 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of acquired intangible assets subject to amortization	A summary of other intangible assets, net, subject to amortization is as follows: December 31, 2021 September 30, 2021 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,421 $ 23,592 $ 62,416 $ 22,633 Trade names, licenses and patents 18,495 9,806 18,489 9,492 Customer lists, customer relationships and supply agreements 54,954 20,887 54,941 19,649 Non-compete 110 37 110 31 Total $ 135,980 $ 54,322 $ 135,956 $ 51,805

Leasing Arrangements (Tables)

Leasing Arrangements (Tables)	3 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule Of Condensed Income Statement Of Operation	The lease costs for these operating leases reflected in our Condensed Consolidated Statements of Operations, as well as the right-of-use Three Months Ended December 31, 2021 2020 Lease costs within cost of sales $ 225 $ 158 Lease costs within operating expenses 388 374 Right-of-use , 218 80
Schedule of weighted average remaining lease term and discount rate	The weighted average remaining lease term for our operating leases and the weighted average discount rate used to measure our operating leases were as follows: December 31, September 30, Weighted average remaining lease term 3.3 years 3.6 years Average discount rate 3.2 % 3.2 %
Schedule of maturities of lease liabilities	Maturities of lease liabilities by fiscal year for the Company’s operating leases were as follows as of December 31, 2021: 2022 (represents remainder of fiscal year) $ 1,687 2023 1,690 2024 1,218 2025 908 2026 316 Thereafter 62 Total lease payments 5,881 Less amount of lease payments representing interest (295 ) Total present value of lease payments $ 5,586
Schedule of supplemental cash flow information related to the companys operating lease liabilities	Supplemental cash flow information related to the Company’s operating leases is as follows: Three Months Ended December 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 627 $ 494

Contingent Obligations and No_2

Contingent Obligations and Non-Current Liabilities (Tables)	3 Months Ended
	Dec. 31, 2021
Contingent Obligations And Non current Liabilities Disclosure [Abstract]
Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet	The grant obligations are reflected in the Condensed Consolidated Balance Sheets as follows: December 31, September 30, Current liabilities $ 765 $ 638 Non-current $ 5,068 $ 5,176

Reportable Segment and Major _2

Reportable Segment and Major Customers Information (Tables)	3 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Consolidated Net Revenues	Three individual Diagnostics and two Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows: Three Months Ended December 31, 2021 2020 Diagnostics Customer A 10 % 12 % Customer B 11 % 10 % Customer C 11 % 11 % Life Science Customer D 14 % 19 % Customer E 23 % 2 % In addition, the two Life Science segment customers, including their affiliates, identified above accounted for greater than 10% of consolidated net revenues as follows: Three Months Ended December 31, 2021 2020 Life Science Customer D 9 % 13 % Customer E 14 % 2 %
Reportable Segment Information	Reportable segment and corporate information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended December 31, 2021 Net revenues - Third-party $ 33,204 $ 55,137 $ — $ — $ 88,341 Inter-segment 34 55 — (89 ) — Operating (loss) income (2,612 ) 26,517 (3,637 ) 15 20,283 Goodwill (December 31, 2021) 94,908 19,805 — — 114,713 Other intangible assets, net (December 31, 2021) 81,656 2 — — 81,658 Total assets (December 31, 2021) 352,318 106,339 — (17 ) 458,640 Three Months Ended December 31, 2020 Net revenues - Third-party $ 30,321 $ 62,596 $ — $ — $ 92,917 Inter-segment 69 18 — (87 ) — Operating (loss) income (1,182 ) 39,797 (3,963 ) 12 34,664 Goodwill (September 30, 2021) 94,904 19,764 — — 114,668 Other intangible assets, net (September 30, 2021) 84,149 2 — — 84,151 Total assets (September 30, 2021) 339,208 110,536 — (22 ) 449,722 (1) Includes selected legal costs of $281 and $1,227 in the three months ended December 31, 2021 and 2020, respectively. (2) Eliminations consist of inter-segment transactions.
Pre-tax Earnings Table	A reconciliation of reportable segment operating (loss) income to consolidated earnings before income taxes for the three months ended December 31, 2021 and 2020, is as follows: Three Months Ended December 31, 2021 2020 Operating (loss) income: Diagnostics segment $ (2,612 ) $ (1,182 ) Life Science segment 26,517 39,797 Eliminations 15 12 Total operating income 23,920 38,627 Corporate expenses (3,637 ) (3,963 ) Interest income 1 9 Interest expense (372 ) (534 ) RADx initiative grant income — 800 Other, net (161 ) (691 ) Consolidated earnings before income taxes $ 19,751 $ 34,248

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 88,341	$ 92,917
Revenue, % change	(5.00%)
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 33,204	30,321
Revenue, % change	10.00%
Diagnostics [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 26,613	23,551
Revenue, % change	13.00%
Diagnostics [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 6,093	6,020
Revenue, % change	1.00%
Diagnostics [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 498	750
Revenue, % change	(34.00%)
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 55,137	62,596
Revenue, % change	(12.00%)
Life Science [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 8,137	18,755
Revenue, % change	(57.00%)
Life Science [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 28,648	32,311
Revenue, % change	(11.00%)
Life Science [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 18,352	$ 11,530
Revenue, % change	59.00%

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 88,341	$ 92,917
Revenue, % change	(5.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 33,204	30,321
Revenue, % change	10.00%
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,752	4,590
Revenue, % change	4.00%
Diagnostics [Member] | Non-molecular assays
Segment Reporting Information [Line Items]
Revenue	$ 28,452	25,731
Revenue, % change	11.00%
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 55,137	62,596
Revenue, % change	(12.00%)
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 31,488	46,029
Revenue, % change	(32.00%)
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 23,649	$ 16,567
Revenue, % change	43.00%

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Disaggregation of Revenue by Disease State (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 88,341	$ 92,917
Revenue, % change	(5.00%)
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 33,204	30,321
Revenue, % change	10.00%
Diagnostics [Member] | Gastrointestinal Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 21,619	15,452
Revenue, % change	40.00%
Diagnostics [Member] | Respiratory Illness Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,380	4,806
Revenue, % change	33.00%
Diagnostics [Member] | Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 78	4,394
Revenue, % change	(98.00%)
Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,127	$ 5,669
Revenue, % change	(10.00%)

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Royalty income	$ 1,040	$ 860
Revenues	88,341	92,917
Lease Elements [Member] | Product Concentration Risk [Member] | Revenues [Member] | Reagent Rental Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 995	$ 880

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Interest Rate Swap [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Measurements [Line Items]
Fair value of interest rate swaps	$ 347	$ 203

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jul. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Finite lived intangible assets amortization expense		$ 2,483	$ 2,221
BreathTek [Member]
Payments to Acquire Businesses, Gross	$ 19,585
Consideration holdback	1,000
Business combination, recognized identifiable assets acquired and liabilities assumed, inventory	9,855
Net revenues		5,611
Net earnings		1,600
BreathTek [Member] | Customer Relationships [Member]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles	$ 9,730
Finite lived intangible assets useful life	5 years
Finite lived intangible assets amortization expense		$ 486

Business Combinations - Consoli

Business Combinations - Consolidated Pro Forma Results Of The Combined Entities (Detail) - BreathTek [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition, Pro Forma Information [Abstract]
Net Revenues	$ 88,341	$ 97,824
Net Earnings	$ 15,340	$ 28,014

Lead Testing Matters - Addition

Lead Testing Matters - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Accrued Recall and related notification payable	$ 4,300		$ 5,100
Legal fees	281	$ 1,227
DOJ Subpoena [Member]
Legal fees	$ 281	$ 1,227
Litigation filing date	April 17, 2018

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 72,729	$ 49,771	$ 63,193	$ 53,514
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,020	1,020
Cash on hand, unrestricted [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 71,709	$ 48,751

Inventories, Net - Components o

Inventories, Net - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Inventory [Line Items]
Raw materials	$ 15,104	$ 14,843
Work-in-process	21,479	25,072
Total	74,198	76,842
Instruments [Member]
Inventory [Line Items]
Finished goods	2,699	2,260
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 34,916	$ 34,667

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Amortization of identifiable assets	$ 2,483	$ 2,221
2022	7,455
2023	9,925
2024	9,920
2025	9,915
2026	8,920
2027	6,645
Increase decrease in goodwill during the period	45
Diagnostics [Member]
Increase decrease in goodwill foreign currency translation adjustment	4
Life Science [Member]
Increase decrease in goodwill foreign currency translation adjustment	$ 41

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 135,980	$ 135,956
Accumulated Amortization	54,322	51,805
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	62,421	62,416
Accumulated Amortization	23,592	22,633
Tradenames, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	18,495	18,489
Accumulated Amortization	9,806	9,492
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	54,954	54,941
Accumulated Amortization	20,887	19,649
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	110	110
Accumulated Amortization	$ 37	$ 31

Leasing Arrangements - Schedule

Leasing Arrangements - Schedule of Condensed Income Statement Of Operation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Condensed Income Statements, Captions [Line Items]
Right-of-use assets, net obtained in exchange for operating lease liabilities	$ 218	$ 80
Lease costs within cost of sales
Condensed Income Statements, Captions [Line Items]
Operating lease cost	225	158
Lease costs within operating expenses
Condensed Income Statements, Captions [Line Items]
Operating lease cost	$ 388	$ 374

Leasing Arrangements - Schedu_2

Leasing Arrangements - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Detail)	Dec. 31, 2021	Sep. 30, 2021
Weighted Average Remaining Lease Term And Weighted Average Discount Rate Used To Measure Operating Lease [Abstract]
Weighted average remaining lease term	3 years 3 months 18 days	3 years 7 months 6 days
Average discount rate	3.20%	3.20%

Leasing Arrangements - Schedu_3

Leasing Arrangements - Schedule of maturities of lease liabilities (Detail) $ in Thousands	Dec. 31, 2021USD ($)
Operating lease liabilities
2022 (represents remainder of fiscal year)	$ 1,687
2023	1,690
2024	1,218
2025	908
2026	316
Thereafter	62
Total lease payments	5,881
Less amount of lease payments representing interest	(295)
Total present value of lease payments	$ 5,586

Leasing Arrangements - Schedu_4

Leasing Arrangements - Schedule Of Supplemental Cash Flow Information Related To The CompanyS Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 627	$ 494

Bank Credit Arrangements - Addi

Bank Credit Arrangements - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 25, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit outstanding		$ 50,000		$ 60,000
Revolving credit facility interest rate percentage		2.22%	2.54%
Original Facility [Member]
Debt Instrument [Line Items]
Line of credit facility borrowing capacity	$ 150,000
Line of credit facility, Expiration date	May 24, 2024
Amended Facility [Member]
Debt Instrument [Line Items]
Line of credit facility borrowing capacity	$ 200,000
Line of credit facility, Expiration date	Oct. 25, 2026

Contingent Obligations and No_3

Contingent Obligations and Non-Current Liabilities - Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Current liabilities	$ 765	$ 638
Liabilities, Noncurrent	$ 5,068	$ 5,176

Contingent Obligations and No_4

Contingent Obligations and Non-Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Sep. 30, 2021
Government grant obligations	$ 5,833	$ 5,814
Breath ID Products [Member]
Percent of breath ID revenue for grant repayment	3.00%
Potential Future Severance Indemnity [Member]
Liability for potential severance indemnity	$ 707	754
Former Chief Executive Officer [Member]
Post employment benefit obligations	$ 1,639	$ 1,676
Maximum [Member] | Long Term Government Grant Obligations [Member]
Percentage of interest on grants	2.02%	2.02%
Minimum [Member] | Long Term Government Grant Obligations [Member]
Percentage of interest on grants	0.58%	0.58%

National Institutes of Health_2

National Institutes of Health Contracts - Additional Information (Detail) - USD ($) $ in Thousands	Feb. 01, 2021	Dec. 31, 2021	Dec. 31, 2020	Jan. 25, 2022	Sep. 30, 2021
Health Contracts Relating To Research And Development [Line Items]
Grant Contract Lease Term	12 months
Grant receipts upon milestone achievement	$ 5,500
RADx grant proceeds offsetting cost of equipment		$ 1,500
Subsequent Event [Member]
Health Contracts Relating To Research And Development [Line Items]
Grant receipts upon milestone achievement				$ 2,500
Maximum [Member] | Subsequent Event [Member]
Health Contracts Relating To Research And Development [Line Items]
Grant receipts upon milestone achievement				$ 8,000
National Institute Of Health [Member] | Other Income Expense [Member]
Health Contracts Relating To Research And Development [Line Items]
Proceeds from reimbursement of research and development expenditure			$ 800
National Institute Of Health [Member] | Reimbursement Of Research And Development Expenditure Accrued [Member]
Health Contracts Relating To Research And Development [Line Items]
Reimbursement of research and development expenditure					$ 1,000

Reportable Segment and Major _3

Reportable Segment and Major Customers Information - Consolidated Net Revenues (Detail) - Customer Concentration Risk [Member] - Revenues [Member]	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Two life science segment customers and its affiliates [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	10.00%	10.00%
Customer A [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	10.00%	12.00%
Customer B [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	11.00%	10.00%
Customer C [Member] | Diagnostics [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	11.00%	11.00%
Customer D [Member] | Life Science [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	14.00%	19.00%
Customer D [Member] | Life Science [Member] | Segment Level [Member] | Two life science segment customers and its affiliates [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	9.00%	13.00%
Customer E [Member] | Life Science [Member] | Segment Level [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	23.00%	2.00%
Customer E [Member] | Life Science [Member] | Segment Level [Member] | Two life science segment customers and its affiliates [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	14.00%	2.00%

Reportable Segment and Major _4

Reportable Segment and Major Customers Information - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two life science segment customers and its affiliates [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	10.00%	10.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	10.00%
Customer Concentration Risk [Member] | Customer B [Member] | Accounts Receivable [Member] | Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			12.00%
Customer Concentration Risk [Member] | Life Science Segment Ten Largest Customer [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	42.00%	37.00%
Customer Concentration Risk [Member] | Life Science Segment Ten Largest Customer [Member] | Sales Revenue, Net [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	67.00%	55.00%
Customer Concentration Risk [Member] | One Single Customer [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	10.00%	10.00%
Customer Concentration Risk [Member] | One Of The Diagnositic Or Life Science Segment Customer [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage		10.00%
Customer Concentration Risk [Member] | Customer D [Member] | Accounts Receivable [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			10.00%
Product Concentration Risk [Member] | Three Diagnostics Product Families [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	32.00%	27.00%

Reportable Segment and Major _5

Reportable Segment and Major Customers Information - Reportable Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net revenues	$ 88,341	$ 92,917
Operating (loss) income	20,283	34,664
Goodwill	114,713		$ 114,668
Other intangible assets, net	81,658		84,151
Total assets	458,640		449,722
Litigation costs	281	1,227
Corporate [Member]
Segment Reporting Information [Line Items]
Operating (loss) income	(3,637)	(3,963)
Eliminations [Member]
Segment Reporting Information [Line Items]
Net revenues	(89)	(87)
Operating (loss) income	15	12
Total assets	(17)		(22)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating (loss) income	23,920	38,627
Operating Segments [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	33,204	30,321
Net revenues	34	69
Operating (loss) income	(2,612)	(1,182)
Goodwill	94,908		94,904
Other intangible assets, net	81,656		84,149
Total assets	352,318		339,208
Operating Segments [Member] | Life Science [Member]
Segment Reporting Information [Line Items]
Net revenues	55,137	62,596
Net revenues	55	18
Operating (loss) income	26,517	$ 39,797
Goodwill	19,805		19,764
Other intangible assets, net	2		2
Total assets	$ 106,339		$ 110,536

Reportable Segment and Major _6

Reportable Segment and Major Customers Information - Pre-tax Earnings Table (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating (loss) income	$ 20,283	$ 34,664
Corporate expenses	(3,637)	(3,963)
Interest income	1	9
Interest expense	(372)	(534)
RADx initiative grant income	0	800
Other, net	(161)	(691)
EARNINGS BEFORE INCOME TAXES	19,751	34,248
Operating Segments [Member]
Operating (loss) income	23,920	38,627
Operating Segments [Member] | Diagnostics [Member]
Operating (loss) income	(2,612)	(1,182)
Operating Segments [Member] | Life Science [Member]
Operating (loss) income	26,517	39,797
Eliminations [Member]
Operating (loss) income	$ 15	$ 12

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes Disclosure [Line Items]
Effective income tax rate continuing operations	22.00%	22.00%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 25, 2022	Feb. 01, 2021
Subsequent Event [Line Items]
Grant receipts upon milestone achievement		$ 5,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Grant receipts upon milestone achievement	$ 2,500
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Grant receipts upon milestone achievement	$ 8,000